Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;6(1):89-101.
doi: 10.1177/2396987320953312. Epub 2020 Oct 11.

Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol

Joanna M Wardlaw  1   2 , Fergus Doubal  1   2 , Rosalind Brown  1   2 , Ellen Backhouse  1   2 , Lisa Woodhouse  3 , Philip Bath  3 , Terence J Quinn  4 , Thompson Robinson  5 , Hugh S Markus  6 , Richard McManus  7 , John T O'Brien  8 , David J Werring  9   10   11 , Nikola Sprigg  3 , Adrian Parry-Jones  12 , Rhian M Touyz  4 , Steven Williams  13 , Yee-Haur Mah  13 , Hedley Emsley  14 ; R4VaD Investigators
Affiliations

Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol

Joanna M Wardlaw et al. Eur Stroke J. 2021 Mar.

Abstract

Background: Stroke commonly affects cognition and, by definition, much vascular dementia follows stroke. However, there are fundamental limitations in our understanding of vascular cognitive impairment, restricting understanding of prevalence, trajectories, mechanisms, prevention, treatment and patient-service needs.

Aims: Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD) is an observational cohort study of post-stroke cognition. We aim to recruit a wide range of patients with stroke, presenting to geographically diverse UK hospitals, into a longitudinal study to determine rates of, and risk factors for, cognitive and related impairments after stroke, to assess potential mechanisms and improve prediction models.

Methods: We will recruit at least 2000 patients within six weeks of stroke with or without capacity to consent and collect baseline demographic, clinical, socioeconomic, lifestyle, cognitive, neuropsychiatric and informant data using streamlined patient-centred methods appropriate to the stage after stroke. We will obtain more detailed assessments at four to eight weeks after the baseline assessment and follow-up by phone and post yearly to at least two years. We will assess diagnostic neuroimaging in all and high-sensitivity inflammatory markers, genetics, blood pressure and diffusion tensor imaging in mechanistic sub-studies.Planned outputs: R4VaD will provide reliable data on long-term cognitive function after stroke, stratified by prior cognition, stroke- and patient-related variables and improved risk prediction. It will create a platform enabling sharing of data, imaging and samples. Participants will be consented for re-contact, facilitating future clinical trials and providing a resource for the stroke and dementia research communities.

Keywords: Stroke; cognition; dementia; observational.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RMT, HE, AP-J, NS, YHM, TR, FD, HSM, None; PB was a co-Chief Investigator of PHADER and reports receiving honoraria from Phagenesis, DiaMedica, Moleac, Nestle, Sanofi; TQ has received investigator initiated funding from BMS and Pfizer for projects on cardiovascular disease and cognition; FD holds an NHS Research Scotland Research Fellowship; DW Honoraria (speaking) from Bayer 2016, 2017, 2018 (talks or debates on ICH, atrial fibrillation, dementia); Honoraria (chairing) from Portola and Bayer (2019); Consultancy fees from Bayer (2017; embolic stroke of undetermined source), Alnylam (2019; CAA), Portola (2019, 2020; andexanet alpha); RM has received BP monitoring equipment for research from Omron and is working with them to develop a telemonitoring system. All fees for this work are paid to his institution.

Figures

Figure 1.
Figure 1.
Flow chart of recruitment and study protocol.
Figure 2.
Figure 2.
Recruitment actual versus target as at 20 March 2020.
See this image and copyright information in PMC

References

    1. Hachinski V, Einhäupl K, Ganten D, et al.. Preventing dementia by preventing stroke: the Berlin Manifesto. Alzheimers Dement 2019; 15: 961–984. - PMC - PubMed
    1. Pendlebury S, Rothwell P, Study OV. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol 2019; 18: 248–258. - PMC - PubMed
    1. Rostamian S, Mahinrad S, Stijnen T, et al.. Cognitive impairment and risk of stroke: a systematic review and meta-analysis of prospective cohort studies. Stroke 2014; 45: 1342–1348. - PubMed
    1. O’Brien JT, Thomas A. Vascular dementia. Focus (Am Psychiatr Publ) 2015; 386: 1698–1706. - PMC - PubMed
    1. Pollock A, St GB, Fenton M, et al.. Top ten research priorities relating to life after stroke. Lancet Neurol 2012; 11: 209. - PubMed

LinkOut - more resources